About Skye Biologics

Future Biologics

Tackling a growing overspend of $100+ billion market, Skye is rapidly advancing multiple future regenerative biological therapies for both surgical and non-surgical applications for all areas of the musculoskeletal system, internal tissue structures and areas where there is a high-unmet medical need and leverages its platform and expertise. We are dedicated and strive to accelerate to market regenerative solutions that improve health outcomes, dramatically improve people's lives in less time and reduce the cost of treatment. A biotech leader since 2010, Skye has grown to be one of the world's leading independent new age biotechnology companies, has reached hundreds of thousands of patients in the US with existing tissue products and is developing a pipeline of medicines with breakaway potential for decades to come.

Active & Future Clinical Trials:
Orthopedic / Sports Medicine / Spine / Foot & Ankle / Wounds / Urology & Gynecology

Learn About our Purpose & Commitment to Improving Patient Quality of Life

Skye Biologics first generation tissue implants have been used in over 250,000 tissue-repair treatments nationwide, to augment and support degenerated or damaged tissues in surgical repairs and non-operative therapy as a potential alternative to surgery.

Our implants performance utilizes a complex BioActive® scaffold. The source of our implants and biologics are derived from a unique and very promising age-zero human biologic material, which has is immune privileged material and immense remodeling potential. 

Our current and future therapeutic product offering provides biologic solutions with ideal handling and delivery options for most clinical challenges, and applications for this technology are continually increasing. When these future therapeutics are applied, they provide a native scaffold structure along with abundant growth factors and BioActive® molecules that support and restore the body's remodeling ability. 

The current tissue transplants and future therapeutic biologics will be utilized in the treatment of musculoskeletal injuries, nerve grafting, scar and adhesion prevention, incision and wound repair, and other applications in orthopaedic, podiatry, neuro and spine, GYN, urologic, colorectal, general, head, and neck, ocular and wound care procedures.

Skye Biologics continues to work together with leading physicians, institutions, hospitals, and corporate partners to identify medical needs and continue to develop and tailor our advanced BioECM® transplant grafts and future biologic therapeutics.